Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2025-12-25 @ 8:34 PM
Study NCT ID:
NCT05266469
Status:
COMPLETED
Last Update Posted:
2025-07-09
First Post:
2022-02-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-26
Start Date Type:
ACTUAL
Primary Completion Date:
2024-11-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-11-11
Completion Date Type:
ACTUAL
First Submit Date:
2022-02-23
First Submit QC Date:
None
Study First Post Date:
2022-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-07
Last Update Post Date:
2025-07-09
Last Update Post Date Type:
ACTUAL